Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 13;42(5):1856–1868. doi: 10.3892/or.2019.7277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhou et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Combined effect of CCR5, CCR6 and CCR9 on the overall survival of patients with early-stage PDAC. Nomogram for predicting 1-, 2- and 3-year events and a prognostic model with risk score, in terms of CCR5, CCR6 and CCR9 expression in early-stage PDAC. (A) Overall survival curves for the combined effect of CCR5 and CCR6. Group A, Low CCR5 + Low CCR6; Group B, Low CCR5 + High CCR6; Group C, High CCR5 + Low CCR6; Group D, High CCR5 + High CCR6. (B) Overall survival curves for the combined effect of CCR5 and CCR9. Group I, Low CCR5 + Low CCR9; Group II, Low CCR5 + High CCR9; Group III, High CCR5 + Low CCR9; Group IV, High CCR5 + High CCR9. (C) Overall survival curves for the combined effect of CCR6 and CCR9. Group a, Low CCR5 + Low CCR9; Group b, Low CCR5 + High CCR9; Group c, High CCR5 + Low CCR9; Group d, High CCR5 + High CCR9. (D) Overall survival curves for the combined effect of CCR5, CCR6 and CCR9. Group 1, Low CCR5 + Low CCR6 + Low CCR9; Group 2, Low CCR5 + Low CCR6 + High CCR9, High CCR5 + Low CCR6 + Low CCR9, and Low CCR5 + High CCR6 + Low CCR9; Group 3, Low CCR5 + High CCR6 + High CCR9, High CCR5 + High CCR6 + Low CCR9, and High CCR5 + Low CCR6 + High CCR9; Group 4, High CCR5 + High CCR6 + High CCR9. (E) Nomogram for predicting 1-, 2- and 3-year events (mortalities) that combine clinical data with CCR5, CCR6 and CCR7 expression. (F) From top to bottom; risk score plot, survival status scatter plot and heat map of the expression levels of CCR5, CCR6 and CCR9 in low- and high-risk groups. (G) Kaplan-Meier curves for low- and high-risk groups. (H) Receiver operating characteristic curve for predicting 1-, 2- and 3-year survival in patients with early-stage PDAC by risk score. CCR, C-C motif chemokine receptor; PDAC, pancreatic ductal adenocarcinoma.

Figure 4. — Combined effect of CCR5, CCR6 and CCR9 on the overall survival of patients with early-stage PDAC. Nomogram for predicting 1-, 2- and 3-year events and a prognostic model with risk score, in terms of CCR5, CCR6 and CCR9 expression in early-stage PDAC. (A) Overall survival curves for the combined effect of CCR5 and CCR6. Group A, Low CCR5 + Low CCR6; Group B, Low CCR5 + High CCR6; Group C, High CCR5 + Low CCR6; Group D, High CCR5 + High CCR6. (B) Overall survival curves for the combined effect of CCR5 and CCR9. Group I, Low CCR5 + Low CCR9; Group II, Low CCR5 + High CCR9; Group III, High CCR5 + Low CCR9; Group IV, High CCR5 + High CCR9. (C) Overall survival curves for the combined effect of CCR6 and CCR9. Group a, Low CCR5 + Low CCR9; Group b, Low CCR5 + High CCR9; Group c, High CCR5 + Low CCR9; Group d, High CCR5 + High CCR9. (D) Overall survival curves for the combined effect of CCR5, CCR6 and CCR9. Group 1, Low CCR5 + Low CCR6 + Low CCR9; Group 2, Low CCR5 + Low CCR6 + High CCR9, High CCR5 + Low CCR6 + Low CCR9, and Low CCR5 + High CCR6 + Low CCR9; Group 3, Low CCR5 + High CCR6 + High CCR9, High CCR5 + High CCR6 + Low CCR9, and High CCR5 + Low CCR6 + High CCR9; Group 4, High CCR5 + High CCR6 + High CCR9. (E) Nomogram for predicting 1-, 2- and 3-year events (mortalities) that combine clinical data with CCR5, CCR6 and CCR7 expression. (F) From top to bottom; risk score plot, survival status scatter plot and heat map of the expression levels of CCR5, CCR6 and CCR9 in low- and high-risk groups. (G) Kaplan-Meier curves for low- and high-risk groups. (H) Receiver operating characteristic curve for predicting 1-, 2- and 3-year survival in patients with early-stage PDAC by risk score. CCR, C-C motif chemokine receptor; PDAC, pancreatic ductal adenocarcinoma.